Pancreatic Cancer Therapeutics – Market Analysis, Patents, Designations, Collaborations, and Other Developments

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.3.1 Marketed Drugs by Route of Administration

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 Breakdown of Primary Research Respondents

2.2.1.1 By industry participant

2.2.1.2 By geography

2.2.2 Key Opinion Leaders (KOLs) Validation

Chapter 3. Executive Summary

Chapter 4. Introduction

4.1 Disease Overview

4.2 Causes and Risk Factors

4.3 Prognosis

4.4 Sign and Symptoms

4.5 Pathophysiology

4.6 Diagnosis

4.7 Treatment

4.8 Treatment Algorithm for Pancreatic Cancer

4.9 Key Drivers

4.9.1 Increasing Incidence of Pancreatic Cancer

4.9.2 Increasing Awareness About the Disease

4.9.3 Rising R&D Investments

4.9.4 Increasing Number of Product Launches

4.10 Key Barriers

4.10.1 Rare Presence of Signs and Symptoms at Early Stage

4.10.2 Patent Expiry of Blockbuster Drugs

4.10.3 High Treatment Cost of Current Treatment

4.11 Opportunities

4.11.1 Aftermath of Current Treatments

4.12 Drug Designations

4.13 Unmet Medical Needs

4.13.1 Improvement in Drug Efficacy

4.13.2 Early Diagnosis

4.13.3 Increasing Usage of Available Approved Therapy

4.13.4 Need of Defined Treatment Algorithm

4.13.5 Improvement Required in 3rd Line Settings

Chapter 5. Marketed Drugs Outlook

5.1 Marketed Drugs Snapshot

5.1.1 By Route of Administration

5.1.2 By Company

Chapter 6. Pancreatic Cancer Marketed Drugs Analysis

6.1 Marketed Drugs Profiles

6.1.1 Sutent

6.1.1.1 Product description

6.1.1.2 Dosage

6.1.1.3 Regulatory milestones

6.1.1.4 Clinical trials and results

6.1.1.5 Patents

6.1.1.6 SWOT analysis

6.1.2 Somatuline Depot

6.1.2.1 Product description

6.1.2.2 Dosage

6.1.2.3 Regulatory milestones

6.1.2.4 Clinical trials and results

6.1.2.5 Strategic developments

6.1.2.6 SWOT analysis

6.1.3 Afinitor

6.1.3.1 Product description

6.1.3.2 Dosage

6.1.3.3 Regulatory milestones

6.1.3.4 Clinical trials and results

6.1.3.5 SWOT analysis

6.1.4 Lutathera

6.1.4.1 Product Description

6.1.4.2 Dosage

6.1.4.3 Regulatory milestones

6.1.4.4 Clinical trials and results

6.1.4.5 Strategic developments

6.1.4.6 SWOT analysis

6.1.5 Onivyde

6.1.5.1 Product description

6.1.5.2 Dosage

6.1.5.3 Regulatory milestones

6.1.5.4 Clinical trials and results

6.1.5.5 Strategic developments

6.1.5.6 Patents

6.1.5.7 SWOT analysis

6.1.6 Abraxane

6.1.6.1 Product description

6.1.6.2 Dosage

6.1.6.3 Regulatory milestones

6.1.6.4 Clinical trials and results

6.1.6.5 Strategic developments

6.1.6.6 SWOT analysis

6.1.7 Tarceva

6.1.7.1 Product description

6.1.7.2 Dosage

6.1.7.3 Regulatory milestones

6.1.7.4 Clinical trials and results

6.1.7.5 Strategic developments

6.1.7.6 Patents

6.1.7.7 Case study

6.1.7.8 SWOT analysis

6.1.8 Gemzar

6.1.8.1 Product description

6.1.8.2 Dosage

6.1.8.3 Regulatory milestones

6.1.8.4 Clinical trials and results

6.1.8.5 Strategic developments

6.1.8.6 Case study

6.1.8.7 SWOT analysis

6.1.9 Fluorouracil

6.1.9.1 Product description

6.1.9.2 Dosage

6.1.9.3 SWOT analysis

6.2 Global Pancreatic Cancer Therapeutics Market Size and Share

6.2.1 Market Size

6.2.2 Market Share

6.3 Challenges Faced by Marketed Drug Manufacturers

6.3.1 Increasing Competition

6.3.2 High Cost of Drugs Targeting Pancreatic Cancer

Chapter 7. Regulatory Framework for Drug Approval

7.1 U.S.

7.2 Europe

7.2.1 Centralized Procedure

7.2.2 Mutual Recognition Procedure

7.2.3 Decentralized Procedure

7.2.4 Nationalized Procedure

7.3 Japan

Chapter 8. Competitive Landscape

8.1 Summary of Strategic Development Activities

8.2 Comparative Analysis of Marketed and Phase III Drugs

8.3 Expected Launch Time of Phase III Clinical Stage Products

8.4 Key Winning Strategies

8.4.1 Technological Advancements

8.4.2 Collaborations and Partnerships

8.4.3 Geographic Expansion through Subsidiaries

8.4.4 Acquisition of Additional Pipeline Products

Chapter 9. Company Profiles

9.1 Pfizer Inc.

9.1.1 Business Overview

9.1.2 Product and Service Offerings

9.2 Eli Lilly and Company

9.2.1 Business Overview

9.2.2 Product and Service Offerings

9.3 Ipsen Pharma

9.3.1 Business Overview

9.3.2 Product and Service Offerings

9.4 Celgene Corporation

9.4.1 Business Overview

9.4.2 Product and Service Offerings

9.5 Astellas Pharma Inc.

9.5.1 Business Overview

9.5.2 Product and Service Offerings

9.6 Novartis AG

9.6.1 Business Overview

9.6.2 Product and Service Offerings

9.7 Spectrum Pharmaceuticals Inc.

9.7.1 Business Overview

9.7.2 Product and Service Offerings

Chapter 10. Appendix

10.1 Recently Organized/Held Seminars and Conferences

10.2 Upcoming Seminars and Conferences

10.3 Sources and References

10.4 Abbreviations

10.5 Related Reports

List of Tables

TABLE 1 PANCREATIC CANCER EPIDEMIOLOGY FOR 7MM (2016-2021)

TABLE 2 PANCREATIC CANCER EPIDEMIOLOGY FOR 7MM (2022-2028)

TABLE 3 DESIGNATIONS

TABLE 4 DESCRIPTION OF SUTENT

TABLE 5 DESCRIPTION OF SOMATULINE DEPOT

TABLE 6 DESCRIPTION OF AFINITOR

TABLE 7 DESCRIPTION OF LUTATHERA

TABLE 8 DESCRIPTION OF ONIVYDE

TABLE 9 PATENTS

TABLE 10 DESCRIPTION OF ABRAXANE

TABLE 11 RESULTS

TABLE 12 DESCRIPTION OF TARCEVA

TABLE 13 SUMMARY OF DISEASE CHARACTERISTICS IN THE STUDY POPULATION

TABLE 14 DESCRIPTION OF GEMZAR

TABLE 15 DESCRIPTION OF FLUOROURACIL

TABLE 16 GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, $M (2018-2023)

TABLE 17 GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, $M (2018-2028)

TABLE 18 COLLABORATIONS AND LICENSING AGREEMENTS

TABLE 19 ACQUISITIONS

TABLE 20 COMPARISON OF THE MARKETED DRUGS, BASED ON EFFICACY

TABLE 21 COMPARISON OF PHASE III DRUGS

TABLE 22 EXPECTED LAUNCH TIME OF PHASE III CLINICAL STAGE PRODUCTS

TABLE 23 PFIZER INC. – AT A GLANCE

TABLE 24 ELI LILLY AND COMPANY – AT A GLANCE

TABLE 25 MARKETED PRODUCTS

TABLE 26 IPSEN PHARMA– AT A GLANCE

TABLE 27 MARKETED PRODUCTS

TABLE 28 CELGENE CORPORATION – AT A GLANCE

TABLE 29 ASTELLAS PHARMA INC.– AT A GLANCE

TABLE 30 MARKETED PRODUCTS

TABLE 31 NOVARTIS AG – AT A GLANCE

TABLE 32 SPECTRUM PHARMACEUTICALS INC.– AT A GLANCE

TABLE 33 MARKETED PRODUCTS

TABLE 34 RECENTLY ORGANIZED SEMINARS AND CONFERENCES

TABLE 35 UPCOMING SEMINARS AND CONFERENCES

TABLE 36 SOURCES AND REFERENCES

TABLE 37 ABBREVIATIONS

List of Figures

FIG 1 RESEARCH METHODOLOGY

FIG 2 BREAKDOWN OF PRIMARY RESEARCH RESPONDENTS, BY INDUSTRY PARTICIPANT

FIG 3 BREAKDOWN OF PRIMARY RESEARCH, BY GEOGRAPHY

FIG 4 BREAKDOWN OF PRIMARY RESEARCH, BY DESIGNATION

FIG 5 PATHWAYS AND CELL FUNCTIONS AFFECTED IN EVERY SINGLE PANCREATIC ADENOCARCINOMA

FIG 6 DIAGNOSTIC ALGORITHM FOR SUSPECTED PANCREATIC CANCER

FIG 7 TREATMENT ALGORITHM FOR PANCREATIC CANCER

FIG 8 PANCREATIC CANCER INCIDENT CASES, BY STAGE FOR 7MM (2016-2028)

FIG 9 UNMET NEEDS – PANCREATIC CANCER

FIG 10 PANCREATIC CANCER MARKETED DRUGS SNAPSHOT, BY ROUTE OF ADMINISTRATION (2019)

FIG 11 KEY PLAYERS AND NUMBER OF THEIR MARKETED DRUG CANDIDATES

FIG 12 GLOBAL PANCREATIC CANCER THERAPEUTICS MARKET SIZE, $M (2018 & 2028)

FIG 13 MARKET SHARE OF PANCREATIC CANCER MARKETED DRUGS (2018)

FIG 14 DRUG DISCOVERY AND APPROVAL PROCESS (PRE-CLINICAL AND CLINICAL TRIALS STAGES)

FIG 15 DRUG APPROVAL PROCESS (NDA REVIEW AND POST-MARKETING STAGES)

FIG 16 NEW DRUG DEVELOPMENT AND APPROVAL PROCESS IN EU

FIG 17 MARKETING AUTHORIZATION PROCEDURES IN EU

FIG 18 CENTRALIZED PROCEDURE FOR DRUG APPROVAL

FIG 19 MUTUAL RECOGNITION PROCEDURE FOR DRUG APPROVAL

FIG 20 DECENTRALIZED PROCEDURE FOR DRUG APPROVAL

FIG 21 NEW DRUG DEVELOPMENT AND APPROVAL PROCESS IN JAPAN

FIG 22 EXPECTED LAUNCH TIME